VanEck Associates’s CRISPR Therapeutics CRSP Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $4.04M | Hold |
83,010
| – | – | ﹤0.01% | 800 |
|
|
2025
Q1 | $2.83M | Hold |
83,010
| – | – | ﹤0.01% | 899 |
|
|
2024
Q4 | $3.27M | Buy |
83,010
+81,464
| +5,269% | +$3.21M | ﹤0.01% | 839 |
|
|
2024
Q3 | $71K | Sell |
1,546
-78,228
| -98% | -$3.59M | ﹤0.01% | 1266 |
|
|
2024
Q2 | $4.31M | Buy |
79,774
+7,830
| +11% | +$423K | 0.01% | 631 |
|
|
2024
Q1 | $4.9M | Buy |
71,944
+4,103
| +6% | +$280K | 0.01% | 588 |
|
|
2023
Q4 | $4.25M | Sell |
67,841
-4,989
| -7% | -$312K | 0.01% | 587 |
|
|
2023
Q3 | $3.31M | Sell |
72,830
-3,933
| -5% | -$178K | 0.01% | 612 |
|
|
2023
Q2 | $4.31M | Sell |
76,763
-5,863
| -7% | -$329K | 0.01% | 545 |
|
|
2023
Q1 | $3.74M | Sell |
82,626
-10,715
| -11% | -$485K | 0.01% | 550 |
|
|
2022
Q4 | $3.79M | Buy |
93,341
+14,084
| +18% | +$572K | 0.01% | 533 |
|
|
2022
Q3 | $5.18M | Sell |
79,257
-47,002
| -37% | -$3.07M | 0.02% | 430 |
|
|
2022
Q2 | $7.67M | Buy |
126,259
+12,198
| +11% | +$741K | 0.02% | 374 |
|
|
2022
Q1 | $7.16M | Buy |
114,061
+10,015
| +10% | +$629K | 0.01% | 431 |
|
|
2021
Q4 | $7.88M | Buy |
104,046
+7,694
| +8% | +$583K | 0.02% | 418 |
|
|
2021
Q3 | $10.8M | Sell |
96,352
-7,807
| -7% | -$874K | 0.03% | 337 |
|
|
2021
Q2 | $16.9M | Sell |
104,159
-14,922
| -13% | -$2.42M | 0.04% | 272 |
|
|
2021
Q1 | $14.5M | Buy |
+119,081
| New | +$14.5M | 0.04% | 278 |
|